Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03528603 · ClinicalTrials.gov registry record · NA
Acute Assessment of Platelet Reactivity After the Intake of Oleocanthal
A NA study, sponsored by University of California, Davis.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT03528603: Completed NA study, sponsored by University of California, Davis.
NCT03528603 is a NA study that has completed, run by University of California, Davis. The registered enrollment target is 26 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03528603, a NA study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
The investigators have previously observed a reduced level of platelet aggregation 2 hours after healthy male individuals were asked to drink extra virgin olive oil (EVOO) that provided a higher level of one specific phenolic known as oleocanthal. This study will help the investigators further determine the effects of oleocanthal-rich EVOO intake on platelet function at 2, 4 and 6 hours after intake with food compared to platelet function in the morning after an overnight fast.
Primary Outcome
Optical platelet aggregometry will be used to measure platelet aggregation. The percent maximal platelet aggregation will be measured. A reduction in maximal aggregation 2, 4 or 6 hours post EVOO intake compared to baseline will represent a reduction in platelet aggregation.
Interventions
- OTHER Oleocanthal-Rich Extra Virgin Olive Oil
- OTHER Oleocanthal-low Extra Virgin Olive Oil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-04-02 |
| Est. Completion | 2024-05-31 |
| Phase | NA |
What the finished NCT03528603 record still lists
NCT03528603 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Oleocanthal-Rich Extra Virgin Olive Oil is the first listed.
NCT03528603 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03528603 about?
NCT03528603 is a clinical study titled "Acute Assessment of Platelet Reactivity After the Intake of Oleocanthal". The investigators have previously observed a reduced level of platelet aggregation 2 hours after healthy male individuals were asked to drink extra virgin olive oil (EVOO) that provided a higher level of one specific phenolic known as oleocanthal. This study will help the investigators further deter...
What is the current status of trial NCT03528603?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2018-04-02. Estimated completion is 2024-05-31.
What interventions are being tested in trial NCT03528603?
The interventions under investigation include: Oleocanthal-Rich Extra Virgin Olive Oil (OTHER), Oleocanthal-low Extra Virgin Olive Oil (OTHER).
Who is sponsoring clinical trial NCT03528603?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03528603's enrollment target sits among peer trials
26 1710th of 2000 higher than 289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI